Therapeutic plasma exchange in Gullian Barre Syndrome: an experience of our centre
DOI:
https://doi.org/10.18203/2349-3933.ijam20162883Keywords:
Gullian barre syndrome, Immunoglobulins, TPEAbstract
Background: Therapeutic plasma exchange (TPE) has been used for the treatment of neurological diseases in which autoimmunity plays a major role. Although, there are several modes of plasmapheresis applicable to Gullian Barre Syndrome (GBS) but no definite guidelines for selecting an optimum mode have been established so far. The aim of the study was to analyze the clinical benefits of plasma exchange (PE) on the patients of GBS and compare the cost effectiveness of TPE over other modalities.
Methods: Records of 36 patients who received TPE between March 2015 to September 2015 were analysed using continuous flow cell separator CS-3000. All the patients had undergone minimum 2 cycles of PE. One plasma volume was exchanged for each cycle.
Results: Out of 36 patients, there were 28 (77.78%) male and 8 (22.22%) females. The mean age of patient was 28.23±1.23 years which range from 12 to 36 years. After TPE on 36 patients, 28 (77.78%) patients clinically improved after first cycle of PE and 5 (13.89%) patients improved after second cycle. Patients who received 4 and 3 cycle of PE experience no complications and >75% and 55-60% patients showed improvement respectively.
Conclusions: The treatment is cost effective in comparison to the available IV immunoglobulins. TPE is an easy and effective treatment in GBS.
References
Doorn PAV, Ruts L, Jacobs BC. Clinical features, pathogenesis and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939-50.
Osterman PO, Fagius J, Safwenberg J, Danersund A, Wallin BG, Nordesjo LO. Treatment of the Guillain-Barré syndrome by plasmapheresis. Arch Neurol. 1982;39(3):148-54.
Durward WF, Burnett AK, Watkins R, Reid JM. Plasma exchange in Guillain-Barré syndrome. Br Med J. 1981;283(6294):794.
Burns TM. Guillain-Barre´ Syndrome. Semin Neurol. 2008;28(2):152-67.
Winer JB, Hughes RA, Greenwood RJ, Perkin GD, Healy MJ. Prognosis in Guillain-Barré syndrome. Lancet. 1985;1(8439):1202-3.
Tharakan J, Ferner RE, Hughes RAC, Winer J, Barnett M, Brown ER et al. PE for Guillain-Barre syndrome. Journal Royal Soc Med. 1989;82:458-61.
Van MFGA. The Guillain-Barre syndrome: plasma exchange or immunoglobulins intravenously. J Neurology Neurosurg Psych. 1994;57:33-4.
Gross ML, Legg NJ, Lockwood MC, Pallis C. The treatment of inflammatory polyneuropathy by plasma exchange. J Neurol Neurosurg Psychiatry. 1982;45(8):675-9.
Kennard C, Newland AC, Ridley A. Treatment of the Guillain-Barré syndrome by plasma exchange. J Neurol Neurosurg Psychiatry. 1982;45(9):847-50.
Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet. 1978;2(8099):1100.
Tharakan J, Tandon M, Maheshwari MC. Plasmapheresis in acute infective polyneuritis. J Assoc Physicians India. 1982;30(3):155-6.
Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Sidén A, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;2(8415):1296-9.
Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I. Plasma exchange as a therapy for Guillain-Barré syndrome with immune complexes. Vox Sang. 1981;41(2):74-8.
Greenwood RJ, Newsom DJ, Hughes RA, Aslan S, Bowden AN, Chadwick DW, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;1(8382):877-9.
Rail D, Stark R, Swash M, Newland A. Improvement in nerve condition after plasma exchange for Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1980;43(12):1147.
